Rotem FranceBusiness Directories,Company Directories

Company Name: Corporate Name:	Rotem France
Company Title:
Company Description:
Keywords to Search:
Company Address:	95, Bd du Général Leclerc,51100 Reims,,France
ZIP Code: Postal Code:
Telephone Number:
Fax Number:
Website:
Email:
Number of Employees:
Sales Amount:
Credit History: Credit Report:
Contact Person:
Remove my name

Company Directories & Business Directories

copy and paste this google map to your website or blog!

Press copy button and paste into your blog or website.
(Please switch to 'HTML' mode when posting into your blog. Examples:
WordPress Example, Blogger Example)

Input Form:Deal with this potential dealer,buyer,seller,supplier,manufacturer,exporter,importer

(Any information to deal,buy, sell, quote for products or service)

Previous company profile:
Rota S.A.R.L.
Rotec France S.A.
Rotelec S.A.

Next company profile:
Rotem S.A.R.L.
Roth Rothelec S.A.S.
Roth S.A.

Company News:

FDA approves fruquintinib in refractory metastatic colorectal . . .
On November 8, 2023, the Food and Drug Administration approved fruquintinib (Fruzaqla, Takeda Pharmaceuticals, Inc ) for adult patients with metastatic colorectal cancer (mCRC) who received prior
Treatment for KRAS G12C-mutated metastatic CRC approved by FDA
The U S Food and Drug Administration has approved sotorasib in combination with panitumumab for the treatment of adult patients with KRAS G12C-mutated metastatic colorectal cancer
FDA APPROVES LUMAKRAS® (SOTORASIB) IN COMBINATION WITH . . .
In June 2017, the FDA approved a refined indication for Vectibix for use in patients with wild-type RAS (defined as wild-type in both KRAS and NRAS as determined by an FDA-approved test for this use) mCRC, specifically as first-line therapy in combination with FOLFOX and as monotherapy following disease progression after prior treatment with
New colorectal cancer treatment approved in the U. S. - Takeda
Takeda announces the FDA has approved a new treatment for adults with previously treated metastatic Colorectal Cancer (mCRC)
FDA Approval Summary: Fruquintinib for the Treatment of . . .
On November 8, 2023, the FDA approved fruquintinib, an inhibitor of vascular endothelial growth factor receptors (VEGFR)-1, −2, and −3, for the treatment of patients with metastatic colorectal cancer (mCRC) who have been previously treated with
FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA . . . - Merck
KEYTRUDA and KEYTRUDA QLEX are each indicated for the treatment of adult patients with unresectable or metastatic MSI-H or dMMR colorectal cancer (CRC) as determined by an FDA-approved test
FDA Approves Sotorasib Plus Panitumumab for KRAS G12C-Mutated . . .
The approval of this treatment could mark a new standard of care for patients with KRAS G12C–mutated metastatic CRC, as the treatment was able to provide longer PFS and improve disease control
The FDA Approves Sotorasib With Panitumumab for Treatment of . . .
CRC is the third leading cause of cancer-related mortality in the United States, accounting for approximately 11% of all diagnoses Although survival outcomes in earlier stages of disease are favorable, those with metastatic disease or mutations have significantly worse outcomes KRAS G12C mutations occurs in an estimated 3% to 4% of patients with mCRC and are among the most common genetic
U. S. FDA Approves Pfizer’s BRAFTOVI® Combination Regimen as . . .
This release contains forward-looking information about the BRAFTOVI® (encorafenib) plus cetuximab and mFOLFOX6 combination and a new indication in the U S for the treatment of patients with metastatic colorectal cancer (CRC) with a BRAF V600E mutation, as detected by an FDA-approved test, including their potential benefits and discussions
FDA Oks Sotorasib Panitumumab in KRAS G12C-Mutant Colorectal . . .
The approval of this combination is supported by data from the phase 3 CodeBreaK 300 study The FDA has approved the combination of sotorasib (Lumakras) and panitumumab (Vectibix) for the treatment of patients with previously treated KRAS G12C-mutated metastatic colorectal cancer (CRC) The approval